Liquidia Co. (NASDAQ:LQDA) Receives Consensus Recommendation of “Buy” from Brokerages

Liquidia Co. (NASDAQ:LQDA) has been given an average rating of “Buy” by the nine brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $25.38.

Several equities analysts have weighed in on LQDA shares. Needham & Company LLC restated a “buy” rating and set a $19.00 target price on shares of Liquidia in a report on Thursday, January 9th. Wells Fargo & Company started coverage on Liquidia in a report on Friday, December 20th. They set an “overweight” rating and a $20.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and set a $29.00 target price on shares of Liquidia in a report on Thursday, November 14th.

Insider Activity

In related news, CFO Michael Kaseta sold 23,370 shares of Liquidia stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $275,298.60. Following the sale, the chief financial officer now directly owns 401,755 shares of the company’s stock, valued at $4,732,673.90. This trade represents a 5.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Rajeev Saggar sold 6,249 shares of Liquidia stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total value of $73,613.22. Following the sale, the insider now directly owns 270,388 shares in the company, valued at approximately $3,185,170.64. This trade represents a 2.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 73,945 shares of company stock valued at $874,403. 30.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Steward Partners Investment Advisory LLC bought a new position in Liquidia during the fourth quarter worth about $59,000. Summit Investment Advisors Inc. raised its stake in shares of Liquidia by 35.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company’s stock valued at $78,000 after acquiring an additional 1,719 shares during the last quarter. D. E. Shaw & Co. Inc. bought a new position in shares of Liquidia in the fourth quarter valued at approximately $142,000. EntryPoint Capital LLC bought a new position in shares of Liquidia in the fourth quarter valued at approximately $154,000. Finally, Walleye Trading LLC raised its stake in shares of Liquidia by 54.7% in the third quarter. Walleye Trading LLC now owns 13,201 shares of the company’s stock valued at $132,000 after acquiring an additional 4,670 shares during the last quarter. Institutional investors own 64.54% of the company’s stock.

Liquidia Trading Up 0.8 %

Shares of NASDAQ:LQDA opened at $15.49 on Friday. Liquidia has a 1 year low of $8.26 and a 1 year high of $16.99. The business has a fifty day simple moving average of $13.95 and a 200 day simple moving average of $11.77. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of -9.50 and a beta of 0.27.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).